Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Finland
  4. Nasdaq Helsinki
  5. Revenio Group Oyj
  6. News
  7. Summary
    REG1V   FI0009010912

REVENIO GROUP OYJ

(REG1V)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Revenio Group Corporation: Invitation to Revenio's audiocast and teleconference in relation to the half-year financial report 2021

07/27/2021 | 02:01am EST

Revenio Group Corporation, Press release, July 27, 2021 at 9.00

Invitation to Revenio’s audiocast and teleconference in relation to the half-year financial report 2021

Revenio Group Corporation’s half-year financial report 2021 on Thursday, 5 August 2021, approximately at 9:00 am.

An audiocast and teleconference for analytics and investors is held in English at 3:00 pm on the same day.

Link to the event: https://revenio.videosync.fi/2021-08-05-revenioq2

Teleconference numbers:
FI: +358 981710310
SE: +46 856642651
UK: +44 3333000804
US: +1 6319131422

PIN: 40296342#

For further information, please contact:
Robin Pulkkinen, CFO, tel. +358 50 505 9932
robin.pulkkinen@revenio.fi
https://www.reveniogroup.fi/en/

Revenio Group in brief
Revenio is a leading company in ophthalmological devices and software solutions. Revenio Group’s ophthalmic diagnostic solutions include intraocular pressure (IOP) measurement devices (tonometers), retinal imaging devices, and perimeters under the iCare brand. In addition, the Group’s eye care software platform Oculo brings together clinical communication, telehealth, remote patient monitoring, and data analytics capabilities.

Revenio Group comprises Revenio Group Corporation, Icare Finland Oy, Icare USA Inc., Revenio Italy S.R.L, CenterVue SpA, Revenio Research Oy, Revenio Australia Pty Ltd, Done Medical Oy and Oscare Medical Oy.

In 2020, the Group’s net sales totaled EUR 61.1 million and its operating profit amounted to EUR 17.1 million. Revenio Group Corporation is listed on Nasdaq Helsinki with the trading code REG1V.

© Modular Finance, source Nordic Press Releases

All news about REVENIO GROUP OYJ
11/26REVENIO GROUP CORPORATION : Revenio Group's financial reporting and Annual General Meeting..
AQ
11/16REVENIO GROUP CORPORATION : The Chairman of the Board of Revenio will resign at the spring..
AQ
10/21REVENIO GROUP CORPORATION : Interim report January 1 - September 30, 2021
AQ
10/19REVENIO GROUP CORPORATION : Invitation to Revenio Group Corporation's audiocast and teleco..
AQ
09/20REVENIO OYJ : Group Corporation - Managers' Transactions
AQ
08/05REVENIO GROUP CORPORATION : Half-year financial report 1 January-30 June 2021
AQ
08/05Revenio Group Oyj Reports Earnings Results for the Second Quarter Ended June 30, 2021
CI
08/04REVENIO GROUP CORPORATION : Revenio updates its financial guidance for 2021
AQ
08/04Revenio Group Corporation Reaffirms Earnings Guidance for the Full Year 2021
CI
07/27REVENIO GROUP CORPORATION : Invitation to Revenio's audiocast and teleconference in relati..
AQ
More news
Financials
Sales 2021 77,2 M 87,4 M 87,4 M
Net income 2021 17,0 M 19,2 M 19,2 M
Net Debt 2021 2,61 M 2,95 M 2,95 M
P/E ratio 2021 87,5x
Yield 2021 0,62%
Capitalization 1 492 M 1 689 M 1 689 M
EV / Sales 2021 19,4x
EV / Sales 2022 16,1x
Nbr of Employees 158
Free-Float 84,3%
Chart REVENIO GROUP OYJ
Duration : Period :
Revenio Group Oyj Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REVENIO GROUP OYJ
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 4
Last Close Price 55,95 €
Average target price 59,87 €
Spread / Average Target 7,00%
EPS Revisions
Managers and Directors
Jouni Erik Toijala President & Chief Executive Officer
Robin Allan Pulkkinen Chief Financial Officer
Pekka Veikko Juhani R÷nkń Chairman
Mika Salkola Director-Research & Development
Ari Isomńki Operations Director
Sector and Competitors
1st jan.Capi. (M$)
REVENIO GROUP OYJ11.23%1 675
SARTORIUS AG57.39%44 339
BIOTAGE AB (PUBL)94.68%1 967
VAREX IMAGING CORPORATION71.16%1 126
CELLAVISION AB (PUBL)10.10%888
908 DEVICES INC.-57.86%670